Price Alert

Biodexa Pharmaceuticals (BDRX)

NASDAQ: BDRX · Real-Time Price · USD

6.02

0.09 (1.52%)

At close: Sep 12, 2025, 3:27 PM

1.52% (1D)

Bid	6.01
Market Cap	18
Revenue (ttm)	n/a
Net Income (ttm)	-5.73M
EPS (ttm)	-135.52
PE Ratio (ttm)	-0.04
Forward PE	n/a
Analyst	n/a

Ask	6.19
Volume	57,846
Avg. Volume (20D)	164,603
Open	6.08
Previous Close	5.93
Day's Range	5.93 - 6.27
52-Week Range	5.00 - 108.90
Beta	0.87

About BDRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BDRX

Website n/a

Full Company Profile

Why Price Moved

2 months ago

+12.13%

Biodexa Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription

2 months ago

+29.4%

Biodexa shares are trading higher after the company enrolled the first patient in its Phase 2a study of Tolimidone.

News

1 week ago · zacks.com

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago · accessnewswire.com

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

CARDIFF, UK / ACCESS Newswire / July 28, 2025 / Familial Adenomatous Polyposis (FAP) is an inherited condition that puts people at a much greater risk of developing colon cancer. If left untreated, th...

2 months ago · accessnewswire.com

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

CARDIFF, UNITED KINGDOM / ACCESS Newswire / June 18, 2025 / When it comes to type 1 diabetes, treating this chronic condition can be difficult. After all, with this type of diabetes, the body's immune...